Showing results (11-20 of 113) with videos related to

Sort By:
Pageof 12
Clinical Genitourinary Cancer|April 26, 2025
Incidence of Bladder Cancer, Healthcare Pathways, and Economic Burden: A Real-World Observational Study From the French National Healthcare System DatabaseAldéric Masoandro Fraslin, Simone Benhamou, Thierry Lebret, et al.
Carcinogenesis|March 25, 2014
Genetic variants in DNA repair pathways and risk of upper aerodigestive tract cancers: combined analysis of data from two genome-wide association studies in European populationsMarie-Claude Babron, Rémi Kazma, Valérie Gaborieau, et al.
Mutagenesis|September 10, 2003
DNA adducts in normal bladder tissue and bladder cancer riskSimone Benhamou, Agnès Laplanche, Bertrand Guillonneau, et al.
The Oncologist|May 17, 2012
Risk, characteristics, and prognosis of breast cancer after Hodgkin's lymphomaNikolaus Veit-Rubin, Elisabetta Rapiti, Massimo Usel, et al.
Journal of Cell Science|December 20, 2007
A homologous recombination defect affects replication-fork progression in mammalian cellsFayza Daboussi, Sylvain Courbet, Simone Benhamou, et al.
Mutagenesis|January 6, 2012
Similar DNA methylation pattern in lung tumours from smokers and never-smokers with second-hand tobacco smoke exposureAsta Scesnaite, Sonata Jarmalaite, Pertti Mutanen, et al.
Breast Cancer Research and Treatment|February 13, 2014
Determinants of genetic counseling uptake and its impact on breast cancer outcome: a population-based studyAurélie Ayme, Valeria Viassolo, Elisabetta Rapiti, et al.
Carcinogenesis|May 12, 2007
Polymorphism discovery in 62 DNA repair genes and haplotype associations with risks for lung and head and neck cancersStefan Michiels, Patrick Danoy, Philippe Dessen, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 22, 2011
Antiestrogen therapy for breast cancer modifies the risk of subsequent cutaneous melanomaCaroline Huber, Christine Bouchardy, Robin Schaffar, et al.
Plos One|February 28, 2019
Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non-muscle-invasive bladder cancer and with low and intermediate EORTC-risk scoreMarie Simon, Pierre-Olivier Bosset, Mathieu Rouanne, et al.
Pageof 12